Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lynparza Tablets 100mg, 150mg CEI, Investigation on Development of Bone Marrow Depression in Patients With Unresectable or Recurrent BRCA Mutated HER2 Negative Breast Cancer Who Have Previously Received Anticancer Chemotherapy

NCT03590938 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03590938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03590938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lynparza Tablets 100mg, 150mg CEI, Investigation on Development of Bone Marrow Depression in Patients With Unresectable or Recurrent BRCA Mutated HER2 Negative Breast Cancer Who Have Previously Received Anticancer Chemotherapy
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
August 14, 2018
Completion date
March 24, 2022
Enrollment
111 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer